Omniab, INC. (OABIW) — SEC Filings

Q: What are the key financial highlights for Omniab, INC.?

Key financial highlights for Omniab, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Omniab, INC.?

Key executives at Omniab, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Omniab, INC. stock?

Risk factors for Omniab, INC. (OABIW) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Omniab, INC.?

Forward-looking statements and predictions from Omniab, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Omniab, INC.. Recent 10-Q filing on Nov 4, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Omniab, INC. on SEC EDGAR

Overview

Omniab, INC. (OABIW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: OmniAb, Inc. (OABIW) reported a significant decline in total revenue for the nine months ended September 30, 2025, falling to $10.29 million from $15.59 million in the prior year, a 34% decrease. This was primarily driven by a drop in service revenue from $9.42 million to $5.03 million and license a

Sentiment Summary

Across 20 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 17 neutral. The dominant filing sentiment for Omniab, INC. is neutral.

Filing Type Overview

Omniab, INC. (OABIW) has filed 4 10-Q, 8 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (20)

OmniAb's Revenue Plunges 34% Amidst Persistent Losses — 10-Q · Nov 4, 2025 Risk: high
OmniAb, Inc. (OABIW) reported a significant decline in total revenue for the nine months ended September 30, 2025, falling to $10.29 million from $15.59 million
OmniAb, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Aug 25, 2025 Risk: medium
On August 24, 2025, OmniAb, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided
OmniAb Revenue Soars 110% in Q2 on Strong Licensing Growth — 10-Q · Aug 6, 2025 Risk: medium
OmniAb, Inc. (OABIW) reported a significant increase in total revenue for the three and six months ended June 30, 2025. Total revenue for Q2 2025 surged to $10.
OmniAb, Inc. Reports on Shareholder Vote — 8-K · Jun 18, 2025 Risk: low
OmniAb, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders on June 17, 2025. The company, formerly known as Avista
OmniAb, Inc. Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
OmniAb, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhi
OmniAb, Inc. Files Definitive Proxy Statement for 2025 Meeting — DEF 14A · Apr 29, 2025 Risk: low
OmniAb, Inc. filed a definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 17, 2025. The company, formerly Avista Public Acquis
OmniAb, Inc. Reports Director Changes and Officer Compensation Updates — 8-K · Apr 21, 2025 Risk: low
OmniAb, Inc. announced on April 18, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the depa
10-K Filing — 10-K · Mar 18, 2025
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
OmniAb, Inc. Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
OmniAb, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Avista Public Acquisition Corp. II, reported financial results for t
OmniAb, Inc. Files Q2 2024 10-Q with Revenue Data — 10-Q · Aug 8, 2024 Risk: medium
OmniAb, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Avista Public Acquisition Corp. II, is focused on commercial physical & b
Avista Capital Partners V Reports 10.1% Stake in OmniAb, Inc. — SC 13D/A · Jul 2, 2024 Risk: medium
On July 2, 2024, Avista Capital Partners V, L.P. and related entities filed an amendment to their Schedule 13D for OmniAb, Inc. The filing indicates a change in
OmniAb Appoints Founder Rothberg as New CEO — 8-K · Jul 1, 2024 Risk: medium
OmniAb, Inc. announced on June 27, 2024, the appointment of Dr. Jonathan M. Rothberg as Chief Executive Officer, succeeding Dr. Anya Schiess. Dr. Rothberg, a fo
OmniAb, Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jun 21, 2024 Risk: low
On June 18, 2024, OmniAb, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The company, formerly known as Avista
OmniAb, Inc. Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
OmniAb, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhi
OmniAb, Inc. Announces 2024 Annual Meeting of Shareholders on June 18, 2024 — DEF 14A · Apr 26, 2024 Risk:
OmniAb, Inc. (OABIW) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. OmniAb, Inc. will hold its 2024 Annual Meeting of Shareholders on June 18
OmniAb, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
OmniAb, Inc. (OABIW) filed a Annual Report (10-K) with the SEC on March 25, 2024. OmniAb, Inc. filed its 2023 Form 10-K on March 25, 2024, reporting on the fisc
OmniAb, Inc. Files 8-K on Financials — 8-K · Mar 20, 2024 Risk: low
OmniAb, Inc. filed an 8-K on March 20, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and e
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
BlackRock Discloses 5.0% Passive Stake in OmniAb, Inc. — SC 13G · Jan 29, 2024
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds a significant stake in OmniAb, Inc. (NASDAQ: OABI). As of December 31, 2023

Risk Profile

Risk Assessment: Of OABIW's 15 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Omniab, INC.'s most recent 10-Q filing (Nov 4, 2025):

Revenue: $10.29M
Net Income: -$50.60M
EPS: N/A
Debt-to-Equity: 0.12
Cash Position: $28.54M
Operating Margin: -517.0%
Total Assets: $309.69M
Total Debt: $32.25M

Key Executives

David Burgstahler
Thompson Dean
Dr. Jonathan M. Rothberg
Dr. Anya Schiess
Matthew W. Foehr

Industry Context

OmniAb operates in the highly competitive biotechnology and drug discovery sector, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this space often rely on platform technologies for antibody discovery and therapeutic development. Success hinges on scientific innovation, successful clinical trials, and strategic partnerships to navigate the path to commercialization.

Top Tags

Biotechnology (3) · governance (3) · shareholder-vote (2) · 10-Q (2) · financials (2) · revenue (2) · financial-reporting (2) · Antibody Discovery (1) · Revenue Decline (1) · Net Loss (1)

Key Numbers

Total Revenue (9 months ended Sep 30, 2025): $10.29M — Decreased 34% from $15.59M in 2024
Net Loss (9 months ended Sep 30, 2025): $50.60M — Increased from $48.97M in 2024
Cash and Cash Equivalents (Sep 30, 2025): $28.54M — Increased from $27.60M at Dec 31, 2024
Research and Development Expenses (9 months ended Sep 30, 2025): $33.85M — Decreased from $41.80M in 2024
General and Administrative Expenses (9 months ended Sep 30, 2025): $22.38M — Decreased from $23.38M in 2024
Proceeds from Private Placement: $28.20M — Contributed to increased cash balance
Common Stock Outstanding (Oct 28, 2025): 143,955,400 — Increased from 121,599,488 at Dec 31, 2024
Total Revenue Q2 2025: $10.5M — 110% increase from Q2 2024
Q2 2025 Revenue Growth: 110% — Year-over-year increase in total revenue
License & Milestone Revenue Q2 2025: $6.0M — 200% increase from Q2 2024
License & Milestone Revenue Growth: 200% — Year-over-year increase in Q2
Service Revenue Q2 2025: $2.5M — 66.7% increase from Q2 2024
Service Revenue Growth: 66.7% — Year-over-year increase in Q2
Total Revenue YTD 2025: $18.0M — 80% increase from YTD 2024
YTD Revenue Growth: 80% — Year-over-year increase for six months ended June 30

Related Companies

OABI

Frequently Asked Questions

What are the latest SEC filings for Omniab, INC. (OABIW)?

Omniab, INC. has 20 recent SEC filings from Jan 2024 to Nov 2025, including 8 8-K, 4 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of OABIW filings?

Across 20 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 17 neutral. The dominant sentiment is neutral.

Where can I find Omniab, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Omniab, INC. (OABIW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Omniab, INC.?

Key financial highlights from Omniab, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for OABIW?

The investment thesis for OABIW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Omniab, INC.?

Key executives identified across Omniab, INC.'s filings include David Burgstahler, Thompson Dean, Dr. Jonathan M. Rothberg, Dr. Anya Schiess, Matthew W. Foehr.

What are the main risk factors for Omniab, INC. stock?

Of OABIW's 15 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 7 low-risk.

What are recent predictions and forward guidance from Omniab, INC.?

Forward guidance and predictions for Omniab, INC. are extracted from SEC filings as they are enriched.